PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.
The landmark PAPILLON trial, conducted at Georgetown University's Lombardi Comprehensive Cancer Center and 231 other international sites, has shown that the drug amivantamab, added to chemotherapy, significantly improves survival for patients with a rare form of lung cancer. This form of lung cancer is difficult to treat and makes up about 1-2% of all advanced non-small cell lung cancers (NSCLC) in the U.S. Historically, the median overall survival for patients with this type of cancer was around 1.5 to 2 years.
However, the trial revealed that with amivantamab plus chemotherapy, the median overall survival increased to 34.3 months, nearly 3 years. Although the statistical significance of this improvement was not reached due to the trial's limited power, the crossover between treatment groups made the benefit more pronounced. Amivantamab is a bispecific antibody, a new class of targeted therapies designed to bind to two different targets.
The trial also highlights the importance of next-generation sequencing, a genomic testing method that identifies rare alterations like the EGFR exon 20 insertion mutation, allowing physicians to match patients with therapies specifically designed for their tumors.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
